The selective vitamin D receptor (VDR) activator, paricalcitol, effectively reduces proteinuria in patients with type 2 diabetes mellitus (T2DM) who have been treated with RAAS inhibitors [6]. The gene discussed is VDR; the disease is type 2 diabetes mellitus.